Inclusion Criteria:  Adult (= or > 18 years old) with NSCLC Untreated Stage IV metastatic disease. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic disease Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation) Programmed death-ligand 1 (PD-L1) TPS Score < 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation) Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 No active brain metastases Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria  Exclusion Criteria:  Mixed small-cell lung cancer and NSCLC histology Active brain metastases from non-brain tumors Myocardial Infarction within 6 months of study Day 1 Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) or known CYP3A4 sensitive substrates or P-gp substrates Therapeutic or palliative radiation therapy within 2 weeks of study day 1 Unable to take oral medication Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans